Welcome
Support Centre
22 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Evaluating fracture risk in asymptomatic and normocalcemic Primary Hyperparathyroidism (PHPT)
ISRCTN ISRCTN66569335
ClinicalTrials.gov identifier
Public title Evaluating fracture risk in asymptomatic and normocalcemic Primary Hyperparathyroidism (PHPT)
Scientific title Evaluating fracture risk in asymptomatic and normocalcemic Primary Hyperparathyroidism (PHPT): a cohort study
Acronym FRIP
Serial number at source 2011/125
Study hypothesis To evaluate comprehensively using X-Ray, Dual X-Ray Absorptiometry (DXA), FRAX® fracture risk tool, falls risk assessment and clinical data, what the fracture risk is in patients with PHPT and evaluate whether, by expert consensus, the advice to manage PHPT is changed – essentially the advisability of immediate parathyroidectomy or long-term monitoring of the condition - in comparison to conventional assessment methods (NIH 2002 criteria)
Lay summary Lay summary under review
Ethics approval Not provided at time of registration
Study design Cross sectional clinical assessment study
Countries of recruitment United Kingdom
Disease/condition/study domain Primary Hyperparathyroidism (PHPT)
Participants - inclusion criteria 1. Patients >18y old
2. Male or female patients
3. Those who have an established diagnosis of a PHPT or must have been assessed by an Endocrinologist or Metabolic Bone Physician and then recommended to have non-surgical management of their PHPT
Participants - exclusion criteria 1. <18 years old
2. Those unable to give informed consent
3. Prisoners
4. Women who are preganant or breast feeding
5. Patients with PHPT who would not be suitable for either PTHx medically on safety grounds or where there are serious concerns about the success of an operation
6. Patients with FHH or other condition causing hypercalcemia
Anticipated start date 01/04/2012
Anticipated end date 31/07/2012
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 50
Interventions Novel assessment methods: The overall term is 'comprehensive fracture risk assessment'. This uses:
1. Lateral spinal radiographs [Dual X-Ray Absorptiometry (DXA)} to evaluate whether previous spinal fractures have occurred
2. A composite fracture risk calculator/algorithm termed FRAX (www.shef.ac.uk/FRAX)
3. A falls risk evaluation
Primary outcome measure(s) Number of participants where clinical advice for PHPT management is changed by the (study) fracture risk assessment, from expert consensus, compared with conventional assessment methods of fracture risk
Secondary outcome measure(s) Validity of DXA-based VDA (Vertebral Deformity Assessment) in identifying vertebral fracture in comparison to gold-standard radiograph assessment
Sources of funding Ipswich Hospital NHS Trust R&D (UK)
Trial website
Publications
Contact name Dr  Gavin  Clunie
  Address Ipswich Hospital
Rheumatology Dept
  City/town Ipswich
  Zip/Postcode IP4 5PD
  Country United Kingdom
  Email gavin.clunie@doctors.org.uk
Sponsor Ipswich Hospital R&D Dept (UK)
  Address Heath Rd
  City/town Ipswich
  Zip/Postcode IP4 5PD
  Country United Kingdom
  Email frances.farnsworth@ipswichhospital.nhs.uk
Date applied 07/12/2011
Last edited 10/02/2012
Date ISRCTN assigned 10/02/2012
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central